RxDoctor Payments Data

Charles Jackson, MD

Family Medicine · Marshall, ARNPI 1720003247

Payments from drug & device makers

$590in general payments, 2019–2025

Across 37 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$111
  • Palette Life Sciences, Inc.$108
  • Alkermes, Inc.$63
  • GSK$61
  • AbbVie$53
  • Takeda Pharmaceuticals U.S.A., Inc.$53
  • plus $142 from 6 others

What the payments were for

  • Food & beverage$590100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$590 in reported general payments places this provider in the 50th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$3,252
Medicare patients
91
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$59,447
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$49,208
JardianceEmpagliflozin68$48,023
Tresiba Flextouch U-200Insulin Degludec20$37,745
JanuviaSitagliptin Phosphate50$35,194
OzempicSemaglutide32$30,554
XareltoRivaroxaban39$23,978
EntrestoSacubitril/Valsartan30$22,470
LinzessLinaclotide38$22,055
FarxigaDapagliflozin Propanediol12$17,276
Humulin R U-500 KwikpenInsulin Regular, Human11$12,852
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$9,804
Lantus SolostarInsulin Glargine,hum.Rec.Anlog62$9,739
RestasisCyclosporine12$7,372
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$7,096

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$46$59,44789 claims
GSKTrelegy Ellipta, Anoro Ellipta$61$56,30492 claims
Novo NordiskOzempic$111$30,55432 claims
AbbVieLinzess, Restasis$53$29,42750 claims
AstraZenecaFarxiga, Symbicort$25$21,18329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Marshall

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →